Idexx Laboratories (IDXX) EBIT Margin (2009 - 2026)

Idexx Laboratories' EBIT Margin history runs 18 years deep, the most recent figure standing at 31.78% for Q1 2026.

• In Q1 2026, EBIT Margin rose 8.0% year-over-year to 31.78%; the TTM figure through Mar 2026 stood at 31.63% (up 248.0% YoY), while the FY2025 annual figure was 31.6%, up 265.0% from the prior year.
• EBIT Margin was 31.78% for Q1 2026 at Idexx Laboratories, up from 28.94% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 33.62% in Q2 2025 to a low of 20.81% in Q2 2022.
• Historically, EBIT Margin has averaged 29.46% across 5 years, with a median of 30.07% in 2023.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin tumbled 1057 bps in 2022, then jumped 1058 bps in 2023.
• A 5-year view of EBIT Margin shows it stood at 27.34% in 2022, then fell by 0 bps to 27.21% in 2023, then grew by 1 bps to 27.42% in 2024, then gained by 6 bps to 28.94% in 2025, then gained by 10 bps to 31.78% in 2026.
• The last three EBIT Margin figures came in at 31.78% (Q1 2026), 28.94% (Q4 2025), and 32.11% (Q3 2025), per Business Quant data.